Compare Repligen Corporation Common Stock (RGEN) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Unilever plc — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Unilever plc trades at $64.09 (market cap $134.00B). The key difference: Unilever plc is far larger — about 12× Repligen Corporation Common Stock's market cap, and Unilever plc pays a 3.4% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Unilever plc for 112 Days on average.
| RGEN | UL | |
|---|---|---|
Market Cap | $11.14B | $134.00B |
Volume | 1,259,263 | 2,393,833 |
Sector | Health | Consumer Staples |
52-Week High | $194.57 | $74.59 |
52-Week Low | $102.87 | $55.05 |
Typical Hold Time | 0 Days | 112 Days |
Enterprise Value | $11.02B | $158.93B |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Unilever (UL) trades at $63.86, up 1.45% on the day, with a bullish technical signal and strong profitability metrics including a 18.32% net income margin and 54.56% ROE. Recent earnings have consistently missed expectations, but the company is undergoing strategic portfolio streamlining, including a planned $65 billion food business merger with McCormick, which is under regulatory scrutiny. Cash flow from operations remains robust at $8.35 billion for 2025, though net cash flow was negative $2.08 billion due to significant investing and financing outflows.
The outlook is mixed: analyst consensus is a 'Hold' with a $66.08 price target, suggesting modest upside, but risks include execution of the McCormick deal, competitive pressures, and recent earnings misses. The stock's valuation at a P/E of 21.87 appears reasonable given its defensive emerging market exposure and high margins, but investor sentiment is cautious pending clearer signs of sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
